Literature DB >> 12013531

The role of osteopontin in breast cancer: clinical and experimental studies.

A B Tuck1, A F Chambers.   

Abstract

Osteopontin (OPN) is a secreted, integrin-binding protein which has been implicated in cancer, as well as other pathologies and some aspects of normal development. Here we focus on the role of OPN in breast cancer. We describe studies that have shown that OPN plays a role in normal mammary gland development as well as in progression of breast cancer. We also summarize studies that have shown that OPN can play a functional role in malignancy of breast cancer. At least some of these effects are mediated by specific cell surface integrins (alpha(v)beta3 vs. alpha(v)beta1 and alpha(v)beta5) and lead to increased cell migration, activation of growth factor/receptor pathways (e.g. HGF and EGF), and increased proteolytic enzyme activity (e.g. uPA). We also summarize clinical studies that show that OPN levels in tumors and blood are elevated in women with metastatic breast cancer and may offer promise as prognostic markers in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12013531     DOI: 10.1023/a:1014734930781

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN: 1083-3021            Impact factor:   2.673


  89 in total

Review 1.  Osteopontin: a versatile regulator of inflammation and biomineralization.

Authors:  C M Giachelli; S Steitz
Journal:  Matrix Biol       Date:  2000-12       Impact factor: 11.583

2.  Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin.

Authors:  D R Senger; C A Perruzzi; A Papadopoulos; D G Tenen
Journal:  Biochim Biophys Acta       Date:  1989-06-13

3.  Phosphorylation, glycosylation, and transglutaminase sites in bovine osteopontin.

Authors:  E S Sørensen; T E Petersen
Journal:  Ann N Y Acad Sci       Date:  1995-04-21       Impact factor: 5.691

4.  The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model.

Authors:  A J Oates; R Barraclough; P S Rudland
Journal:  Oncogene       Date:  1996-07-04       Impact factor: 9.867

5.  Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration.

Authors:  M Yebra; G C Parry; S Strömblad; N Mackman; S Rosenberg; B M Mueller; D A Cheresh
Journal:  J Biol Chem       Date:  1996-11-15       Impact factor: 5.157

6.  Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line.

Authors:  H Chen; Y Ke; A J Oates; R Barraclough; P S Rudland
Journal:  Oncogene       Date:  1997-04-03       Impact factor: 9.867

7.  Osteopontin expression and distribution in human carcinomas.

Authors:  L F Brown; A Papadopoulos-Sergiou; B Berse; E J Manseau; K Tognazzi; C A Perruzzi; H F Dvorak; D R Senger
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

8.  Osteopontin expression in a group of lymph node negative breast cancer patients.

Authors:  A B Tuck; F P O'Malley; H Singhal; J F Harris; K S Tonkin; N Kerkvliet; Z Saad; G S Doig; A F Chambers
Journal:  Int J Cancer       Date:  1998-10-23       Impact factor: 7.396

9.  The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro.

Authors:  L Liaw; M P Skinner; E W Raines; R Ross; D A Cheresh; S M Schwartz; C M Giachelli
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

Review 10.  Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene.

Authors:  R Patarca; R A Saavedra; H Cantor
Journal:  Crit Rev Immunol       Date:  1993       Impact factor: 2.214

View more
  44 in total

1.  Pre- and post-translational regulation of osteopontin in cancer.

Authors:  Pieter H Anborgh; Jennifer C Mutrie; Alan B Tuck; Ann F Chambers
Journal:  J Cell Commun Signal       Date:  2011-04-26       Impact factor: 5.782

2.  Override of the osteoclast defect in osteopontin-deficient mice by metastatic tumor growth in the bone.

Authors:  Tajneen Natasha; Misty Kuhn; Owen Kelly; Susan R Rittling
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

3.  Combined Proteomics and Transcriptomics Identifies Carboxypeptidase B1 and Nuclear Factor κB (NF-κB) Associated Proteins as Putative Biomarkers of Metastasis in Low Grade Breast Cancer.

Authors:  Pavel Bouchal; Monika Dvořáková; Theodoros Roumeliotis; Zbyněk Bortlíček; Ivana Ihnatová; Iva Procházková; Jenny T C Ho; Josef Maryáš; Hana Imrichová; Eva Budinská; Rostislav Vyzula; Spiros D Garbis; Bořivoj Vojtěšek; Rudolf Nenutil
Journal:  Mol Cell Proteomics       Date:  2015-04-22       Impact factor: 5.911

4.  Elevated osteopontin expression and proliferative/apoptotic ratio in the colorectal adenoma-dysplasia-carcinoma sequence.

Authors:  Gábor Valcz; Ferenc Sipos; Tibor Krenács; Jeannette Molnár; Arpád V Patai; Katalin Leiszter; Kinga Tóth; Norbert Solymosi; Orsolya Galamb; Béla Molnár; Zsolt Tulassay
Journal:  Pathol Oncol Res       Date:  2010-03-27       Impact factor: 3.201

5.  Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer.

Authors:  Bai Zhao; Tiemin Sun; Fanjuan Meng; Aibing Qu; Chunling Li; Hui Shen; Yu Jin; Wenxin Li
Journal:  J Cancer Res Clin Oncol       Date:  2011-01-05       Impact factor: 4.553

6.  Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435.

Authors:  Lalita A Shevde; Rajeev S Samant; Jason C Paik; Brandon J Metge; Ann F Chambers; Graham Casey; Andra R Frost; Danny R Welch
Journal:  Clin Exp Metastasis       Date:  2006-07-09       Impact factor: 5.150

7.  A new model for lymphatic metastasis: development of a variant of the MDA-MB-468 human breast cancer cell line that aggressively metastasizes to lymph nodes.

Authors:  Sharon A Vantyghem; Alison L Allan; Carl O Postenka; Waleed Al-Katib; Michael Keeney; Alan B Tuck; Ann F Chambers
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

8.  Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells.

Authors:  Priyanka Sharma; Santosh Kumar; Gopal C Kundu
Journal:  Mol Cancer       Date:  2010-07-07       Impact factor: 27.401

9.  Single-step nanoplasmonic VEGF165 aptasensor for early cancer diagnosis.

Authors:  Hansang Cho; Erh-Chia Yeh; Raghu Sinha; Ted A Laurence; Jane P Bearinger; Luke P Lee
Journal:  ACS Nano       Date:  2012-08-21       Impact factor: 15.881

Review 10.  Cancer and the tumor microenvironment: a review of an essential relationship.

Authors:  Flaubert Mbeunkui; Donald J Johann
Journal:  Cancer Chemother Pharmacol       Date:  2008-12-14       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.